BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16728567)

  • 1. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
    Labrie F
    Endocr Relat Cancer; 2006 Jun; 13(2):335-55. PubMed ID: 16728567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Labrie F
    Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):584-93. PubMed ID: 17643129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
    Labrie F; Luu-The V; Labrie C; Simard J
    Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHEA, important source of sex steroids in men and even more in women.
    Labrie F
    Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is dehydroepiandrosterone a hormone?
    Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
    J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of the new selective estrogen receptor modulators.
    Palacios S
    Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.
    Fuqua SA; Russo J; Shackney SE; Stearns ME
    Postgrad Med; 2001 Mar; Spec No():3-10. PubMed ID: 11296736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tamoxifen and breast cancer].
    Nechushtan H; Peretz T
    Harefuah; 2002 Aug; 141(8):718-20, 761, 760. PubMed ID: 12222137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
    Labrie F
    J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SERM--selective estrogen receptor modulators].
    Kønig KB; Eiken PA; Schwarz P
    Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.